Jinal Kamani’s Post

Immunovia completes development of its pancreatic cancer detection test after substantially increasing test accuracy

Great news for bladder cancer patients! A new study shows that Keytruda, an immunotherapy drug, nearly doubles the time people with high-risk, muscle-invasive bladder cancer remain cancer-free after surgery. This breakthrough offers hope and an alternative for those unable to undergo standard chemotherapy. Find out how this treatment could make a life-changing difference. Read more at https://lnkd.in/gAyQWQMq

In the neoadjuvant setting, the meta-analysis supported the use of an ICI alongside chemotherapy in patients with TNBC and HR–positive, HER2–negative disease, but not among patients with HER2–positive disease. In the adjuvant setting, the analysis revealed no significant survival advantage among patients who continued ICI therapy after surgery, regardless of whether patients achieved a pCR or had residual disease. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis JAMA Oncol. 2024;10(10):1331-1341. doi:10.1001/jamaoncol.2024.3456

Impact of Dual Immunotherapies Before Surgery in HR+/HER2-negative Breast Cancer In a new study, researchers from the University of Texas MD Anderson Cancer Center, Brigham and Women’s Hospital, Dana-Farber Brigham Cancer Center, and Harvard Medical School aimed to assess the feasibility of enrolling untreated patients with stage II or III HR+/HER2-negative breast cancer for upfront treatment with combined PD-L1/CTLA-4 checkpoint inhibition before standard neoadjuvant chemotherapy and surgery. Their research paper, published in Oncotarget’s Volume 15 on March 19, 2024, was entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” “Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. [...] The trial was stopped early after 3 of 8 patients experienced immunotherapy-related toxicity or suspected disease progression [...]” Blog synopsis ⬇️ https://lnkd.in/gySFB_pE #cancerresearch #breastcancer #chemotherapy #immunotherapy #oncology #openaccess #openscience #peerreviewed #publication #publishing #meded

More practice-changing results from the KEYNOTE-522 trial. 🎉 Such great news for patients with triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer. There’s very few treatment options for TBNC, so having one that provides improved outcomes with fewer side effects than chemotherapy is significant. Most remarkable, patients who still had residual tumor at surgery following neoadjuvant treatment received the most benefit in terms of overall survival. #BreastCancer #TNBC #TripleNegativeBreastCancer #Keytruda #ClinicalTrials #ClinicalResearch https://lnkd.in/g58Q3JqW

Don Dizon, MD, Professor of Medicine and Surgery, shared pivotal updates from the BrUOG 354 trial at the 2024 ASCO Annual Meeting. The trial's findings highlight the efficacy of combining immunotherapy agents nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with ovarian clear cell carcinoma, achieving a notable overall response rate with a familiar safety profile. This research is a significant step towards improved treatment options for aggressive ovarian cancers. Explore the details of this promising study and its implications for the future of cancer therapy. #OvarianCancer #Immunotherapy #MedicalResearch

Early detection programs for lung cancer improve survival rates. We looked at patients in the Mississippi Delta undergoing curative-intent surgery for lung cancer and found those diagnosed through screening and incidental nodule programs had higher five-year survival rates (87% and 72%) compared to non-program pathways (65%). The results suggest no evidence of over-diagnosis bias, highlighting the effectiveness of structured early detection programs. Congrats Olawale Akinbobola on your article, “Outcomes of resected lung cancer diagnosed through screening and incidental pulmonary nodule programs in a Mississippi Delta cohort,” being published in JTOCRR! https://lnkd.in/d7m3uU6x

#TrendingWithImpact: On March 19, 2024, researchers from the University of Texas MD Anderson Cancer Center, Brigham and Women’s Hospital, Dana-Farber Brigham Cancer Center, and Harvard Medical School published a new research paper in Oncotarget, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” “[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]” #PressRelease: https://lnkd.in/gTzuxnz5 #cancerresearch #breastcancer #cancerpatients #surgery #chemotherapy #immunotherapy #oncology #openaccess #openscience #peerreviewed #journal #publication #publishing #meded

Researchers at University College London (UCL) and University College London Hospitals (UCLH) have discovered that an immunotherapy drug, pembrolizumab, significantly increases the number of patients who are cancer-free after surgery for bowel cancer, according to interim results from the NEOPRISM-CRC phase II clinical trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The study investigated whether pembrolizumab could improve outcomes for patients with stage two or stage three MMR deficient/MSI-High bowel cancer. This genetic profile, present in 10–15 percent of stage two or three bowel cancer patients, represents about 2,000–3,000 cases annually in the U.K. The trial included 32 patients from five U.K. hospitals who were treated with pembrolizumab for nine weeks before surgery instead of the usual combination of surgery and chemotherapy. The results were remarkable: over 50 percent of the patients treated with pembrolizumab showed no signs of cancer after surgery, a significant improvement compared to just four percent in similar studies involving preoperative chemotherapy. All patients remained cancer-free for many months post-surgery, with the median cancer-free period being 9.7 months, ranging from 5.3 to 19 months. #immunotherapy #cancerfree #immunotherapy

This #QPS blog post outlines #Clinicaltrial results that show that pembrolizumab, an immunotherapy drug used to treat cancer, might eliminate the need for surgery for patients with colorectal #cancer. For more, visit https://shorturl.at/F04Hm or email [email protected]. #oncology